Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Genome characterization of T-ALL patients

Petri Pölönen • 9 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Rare Diseases

Petri Pölönen, PhD, St. Jude’s Research Hospital, Memphis, TN, discusses the results of a study which used whole genome sequencing (WGS), whole exome sequencing (WES), and transcriptome sequencing to characterize the genome of pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL). Dr Pölönen highlights novel T-ALL driver genes and genomic alterations that were identified. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Petri Pölönen

1:33
Using WGS and transcriptome sequencing to improve prognostic classification in T-ALL
Petri Pölönen • 9 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals